TY - JOUR
T1 - Phosphodiesterase type 5 inhibitors and kidney disease
AU - Afsar, Baris
AU - Ortiz, Alberto
AU - Covic, Adrian
AU - Gaipov, Abduzhappar
AU - Esen, Tarik
AU - Goldsmith, David
AU - Kanbay, Mehmet
N1 - Funding Information:
AO was supported by PI13/00047, PIE13/00051, ISCIII-RETIC REDinREN RD12/0021 Fondos FEDER, S2010/BMD-2378, FRIAT-IRSIN, and Programa Intensificación Actividad Investigadora (ISCIII/Agencia Laín-Entralgo/CM).
Publisher Copyright:
© 2015, Springer Science+Business Media Dordrecht.
PY - 2015/9/26
Y1 - 2015/9/26
N2 - Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.
AB - Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin–angiotensin system blockers. However, current standard therapeutic options may not be enough for preventing CKD progression in a subset of patients making necessary to develop novel therapeutic options to further slow renal function loss. Phosphodiesterase type 5 (PDE5) inhibitors represent a class of drugs traditionally used to treat erectile dysfunction and pulmonary hypertension. However, recent evidence suggests that PDE5 inhibitors may have additional therapeutic effects, such as cardioprotection and cerebrovascular protection. In the current review, we summarize PDE5 inhibitors’ utility in disease states and clinical conditions related to kidney disease such as systemic hypertension and acute and chronic kidney injury and discuss the mechanisms explaining possible kidney protective roles of PDE5 inhibitors. A recently completed phase 2 trials demonstrated that the long-acting PDE5 inhibitor PF-00489791 decreased albuminuria in patients with overt diabetic nephropathy when added on top of renin–angiotensin system blockade.
KW - Diabetic nephropathy
KW - Hypertension
KW - Kidney protection
KW - Phosphodiesterase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84940440236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84940440236&partnerID=8YFLogxK
U2 - 10.1007/s11255-015-1071-4
DO - 10.1007/s11255-015-1071-4
M3 - Review article
C2 - 26242375
AN - SCOPUS:84940440236
SN - 0301-1623
VL - 47
SP - 1521
EP - 1528
JO - International Urology and Nephrology
JF - International Urology and Nephrology
IS - 9
ER -